aTyr Pharma Shareholders Authorize Discretionary Reverse Stock Split at a Ratio of 1-for-10 to 1-for-50
Key Facts
aTyr Pharma shareholders on October 16 authorized the board to conduct a discretionary reverse stock split, in a move aimed at addressing Nasdaq’s continued listing requirements. The company’s filing with the U.S. Securities and Exchange Commission showed that the vote ended with 52,451,734 shares in favor, 5,234,645 votes against and 228,991 shares abstaining. The resolution does not mean the split was carried out, and it did not specify the 1-for-40 ratio cited in the first draft of the news. The authorization allows the board to choose a ratio from 1-for-10 to 1-for-50. The move comes as the company seeks to regain compliance with Nasdaq’s minimum bid price requirement.
The authorization gives the board the power to carry out or abandon the split within one year of shareholder approval, according to the proxy statement filed with the SEC. Choosing a specific ratio within the authorized range does not require a new shareholder vote. The final decision, including the option not to conduct the split, therefore rests with the board. A total of 57,915,370 shares were present or represented by proxy at the October 16 meeting, equivalent to about 59.04% of shares outstanding on the record date. The figures put shareholder approval in the context of a meeting attended by a majority of the outstanding shares, according to the filing.
The immediate regulatory rationale is Nasdaq’s notice giving the company an additional compliance period ending November 30, 2026. aTyr must regain a bid price of at least $1.00 per share and remain at or above that level for at least 10 consecutive business days. The company said in its proxy statement that noncompliance could lead to delisting, and that over-the-counter trading could harm the stock’s liquidity because those markets “are generally considered less efficient.” Shares of ATYR closed at $0.1534 on October 26, according to EL7 data. The deadline gives the board a defined period to decide whether to use the authorization, while the Nasdaq price requirement remains in force.
The company says any split would reduce the number of shares held by each shareholder but would not change their ownership percentage in the company, except to the extent that fractional shares are rounded. Authorized shares would remain unchanged, meaning that reducing the number of shares outstanding would make the number of authorized shares available for issuance effectively larger relative to shares outstanding. The company warned that the post-split share price might not rise in proportion to the reduction in share count and might not exceed or remain above Nasdaq’s $1.00 threshold. It added that the lower number of shares outstanding could negatively affect liquidity and could increase the number of shareholders holding fewer than 100 shares. The authorization alone therefore does not settle the question of compliance or the action’s effect on trading.
The listing issue comes alongside a financial restructuring and a drug development program that still requires funding. On August 7, aTyr announced an expected workforce reduction of about 60% and said the measures would reduce annual operating expenses by about $13 million beginning in the fourth quarter of 2026. Cash and cash equivalents, restricted cash and available-for-sale investments totaled $58.9 million on June 30, and the company estimated at the time that its resources would cover known obligations for at least one year from the reporting date. In its clinical program, the company said the EFZO-FIT trial did not meet its primary endpoint and that the U.S. Food and Drug Administration considered the study a failure for that reason. The company plans a Phase 3 study with a narrower patient population.
On September 24, aTyr said it had reached alignment with the U.S. Food and Drug Administration on a Phase 3 study protocol for efzofitimod and expected to begin study activities in the fourth quarter of 2026. The study is planned to be randomized, double-blind and placebo-controlled, to last 54 weeks and to enroll up to about 372 patients. The company said, however, that developing the study would require additional capital, which could come through equity or debt issuance, grants or partnerships. That puts the split decision among a set of financing and listing considerations, without establishing that the board has chosen a ratio or implementation date. The next regulatory deadline cited in the filings is November 30, 2026, when Nasdaq’s compliance period for regaining the minimum bid price requirement ends.